About Gain Therapeutics, Inc.
https://www.gaintherapeutics.comGain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders.
CEO
Gene Mack
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
JONES FINANCIAL COMPANIES LLLP
Shares:676.82K
Value:$1.49M
GREENLIGHT CAPITAL INC
Shares:588.41K
Value:$1.29M
DME CAPITAL MANAGEMENT, LP
Shares:566.13K
Value:$1.25M
Summary
Showing Top 3 of 42
About Gain Therapeutics, Inc.
https://www.gaintherapeutics.comGain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.76M ▲ | $-5.28M ▲ | 0% | $-0.15 ▲ | $-4.71M ▲ |
| Q2-2025 | $0 | $2.37M ▲ | $-5.81M ▼ | 0% | $-0.19 ▼ | $-5.09M ▼ |
| Q1-2025 | $0 | $2.15M ▼ | $-4.53M ▼ | 0% | $-0.16 ▼ | $-4.36M ▼ |
| Q4-2024 | $0 | $3.31M ▼ | $-3.77M ▲ | 0% | $-0.14 ▲ | $-3.24M ▲ |
| Q3-2024 | $0 | $4.18M | $-4.49M | 0% | $-0.17 | $-4.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $8.81M ▲ | $10.97M ▲ | $5.06M ▼ | $5.91M ▲ |
| Q2-2025 | $6.69M ▼ | $9.83M ▼ | $6.14M ▲ | $3.7M ▼ |
| Q1-2025 | $9.07M ▼ | $11.62M ▼ | $5.84M ▲ | $5.78M ▼ |
| Q4-2024 | $10.39M ▼ | $12.12M ▼ | $4.78M ▼ | $7.34M ▼ |
| Q3-2024 | $12.05M | $14.37M | $5.46M | $8.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.28M ▲ | $-4.93M ▲ | $0 | $7.03M ▲ | $2.11M ▲ | $-4.93M ▲ |
| Q2-2025 | $-5.81M ▼ | $-5.1M ▼ | $0 | $2.47M ▲ | $-2.37M ▼ | $-5.1M ▼ |
| Q1-2025 | $-4.53M ▼ | $-3.82M ▼ | $0 ▲ | $2.4M ▲ | $-1.31M ▲ | $-3.82M ▼ |
| Q4-2024 | $-3.77M ▲ | $-3.45M ▲ | $-43.45K ▼ | $2.31M ▲ | $-1.67M ▲ | $-3.46M ▲ |
| Q3-2024 | $-4.49M | $-6.08M | $-1 | $808.68K | $-4.88M | $-6.08M |
CEO
Gene Mack
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
JONES FINANCIAL COMPANIES LLLP
Shares:676.82K
Value:$1.49M
GREENLIGHT CAPITAL INC
Shares:588.41K
Value:$1.29M
DME CAPITAL MANAGEMENT, LP
Shares:566.13K
Value:$1.25M
Summary
Showing Top 3 of 42